Clinical Application: Weight Management Tips and Tricks

Understand the importance of clinical application of weight management for achieving optimal health and well-being in your life.

Abstract

Obesity is a chronic, relapsing, and multifactorial disease that has reached epidemic proportions. In this educational post, I will explore the complex nature of obesity, delving into its neuroendocrine, metabolic, and genetic underpinnings. We will discuss the latest research from leading experts in the field, focusing on modern, evidence-based pharmacological strategies for weight management, including advanced GLP-1 and dual GIP/GLP-1 receptor agonists. A significant focus will be placed on confronting the pervasive issue of weight bias and stigma in healthcare, which hinders effective treatment. I will also explain the unique, integrative approach we take at Injury Medical Clinic PA in El Paso, Texas. I will detail how my role as a Doctor of Chiropractic and Advanced Practice Registered Nurse, in collaboration with our Medical Director, Dr. Maria Guadalupe Cardenas, MD, an experienced internist, creates a comprehensive care model. We combine integrative chiropractic care, medical oversight, functional medicine, and personalized lifestyle interventions to provide a holistic and powerful path toward sustainable health. This post also addresses the diagnosis and treatment of Binge Eating Disorder (BED), a common comorbidity, and outlines our practical, step-by-step approach to achieving durable results.

Our Collaborative Care Model at Injury Medical Clinic PA

At Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, we have cultivated a multidisciplinary environment dedicated to providing comprehensive and patient-centered care. I am Dr. Alex Jimenez, and my credentials as a Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), and board-certified Family Nurse Practitioner (FNP-BC), along with certifications in Functional Medicine (CFMP, IFMCP), allow me to view health through multiple lenses. Our care model reflects the reality of complex patients—weight concerns seldom exist in isolation. They intersect with pain, sleep disruption, mood, metabolic disease, and life stressors.

Crucial to our practice is the collaborative relationship with our Medical Director, Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is Board Certified in Internal Medicine and brings over 40 years of invaluable clinical experience to our team. Her role as a collaborative physician (NPI #1164426749, Texas MD License #J2933) provides essential medical oversight, ensuring that our integrative protocols are both safe and effective. This MD-DC collaboration is a cornerstone of modern integrative medicine, allowing us to bridge the gap between conventional medical treatments and holistic, non-invasive therapies. She oversees medical safety, diagnostics, and pharmacotherapy, ensuring alignment with guidelines, comorbidities, and insurance pathways.

Together, our team integrates:

• Integrative Chiropractic Care: I focus on musculoskeletal alignment, nervous system function, and biomechanical balance, which are often compromised by excess weight.
• Medical Oversight: Cardenas provides medical direction, oversees pharmacological considerations, evaluates contraindications, and ensures our care plans meet the highest standards of medical practice.
• Functional Medicine: We dig deep to identify the root causes of dysfunction, such as hormonal imbalances, gut dysbiosis, and metabolic issues that contribute to weight gain.
• Personal Injury & Rehabilitation: Our expertise in injury care allows us to address the biomechanical strain and pain conditions, like osteoarthritis, that frequently accompany obesity.

This synergistic approach ensures safety-first, whole-person weight management, allowing us to create truly individualized treatment plans that address not just the number on the scale, but the entire person—mind, body, and spirit.

Understanding Obesity as a Chronic, Treatable Disease

For too long, obesity has been viewed through a simplistic lens of willpower and personal failure. However, a wealth of modern research has firmly established that obesity is a chronic, progressive, relapsing, and treatable disease. The idea that the condition vanishes when a patient stops their medication is as misguided as expecting hypertension to remain controlled after ceasing antihypertensive drugs. The body’s systems have been altered, and ongoing management is key.

The complexity of obesity emerges from several intertwined systems:

• Neurobehavioral and Neuroendocrine: Powerful hormones regulate appetite, satiety, and energy expenditure.
• Metabolic: Conditions like insulin resistance impair the body’s ability to use fuel efficiently, promoting fat storage.
• Inflammatory: Excess visceral fat secretes pro-inflammatory signals that worsen metabolic health.

At its core, increased abnormal body fat promotes adipose tissue dysfunction, a key driver of the disease’s chronic nature. This dysfunction leads to a cascade of adverse health consequences, including:

• Metabolic: Type 2 diabetes, high cholesterol, and cardiovascular disease.
• Biomechanical: Osteoarthritis, back pain, and sleep apnea.
• Psychosocial: Depression, anxiety, and social isolation, often exacerbated by societal stigma.

In the United States, the statistics are alarming. According to recent data, 41.9% of the population is classified as obese (BMI> 30), and 9.2% suffer from severe obesity (BMI> 40). This is not just a health issue; it is a crisis that demands a more sophisticated and compassionate approach from healthcare providers.

The Complex Web of Appetite Regulation

To truly grasp why “eat less, move more” is an oversimplified and often ineffective mantra, we must look at the intricate biological systems that regulate appetite and energy balance. Your body is not a simple calculator of calories in versus calories out; it is a highly intelligent system constantly seeking homeostasis. When we talk about appetite, we are referring to a complex symphony conducted by powerful neuroendocrine hormones. Imagine trying to override your body’s command to breathe consciously—that’s the level of biological force our patients are up against.

Key players in this system include:

• Ghrelin: Often called the “hunger hormone,” it is produced in the stomach and signals the brain to stimulate appetite.
• Leptin: Produced by fat cells, leptin signals satiety, or fullness, to the brain. In obesity, leptin resistance can develop, in which the brain no longer responds to this signal, leading to persistent hunger despite adequate energy stores.
• GLP-1 (Glucagon-Like Peptide-1): This gut hormone is released after eating and plays a crucial role in promoting satiety, slowing stomach emptying, and regulating blood sugar. Many of the newest and most effective obesity medications target this very pathway.
• Cortisol: The “stress hormone” can increase appetite, particularly for high-calorie, comfort foods, and promote fat storage, especially in the abdominal area.

When any one of these hormonal signals goes awry, the entire system can be thrown off balance, making it incredibly difficult for an individual to maintain a healthy weight through behavioral changes alone. This is where modern pharmacotherapy, combined with lifestyle and functional medicine, becomes a game-changer.

The Invisible Barrier: Weight Bias in Healthcare

One of the most significant and heartbreaking obstacles in treating obesity is not a lack of knowledge or tools, but a deeply ingrained cultural problem: weight bias. This is the last socially acceptable form of discrimination, and it runs rampant within the healthcare system. The numbers are shocking. Out of an estimated 100 million people with obesity in the U.S., less than 1% receive a prescription for an anti-obesity medication. Less than 300,000 undergo bariatric surgery, despite millions qualifying.

Why this systemic failure?

• Provider Bias: There’s a pervasive, often unconscious, belief that obesity is a moral failing or a lack of willpower. This leads providers to dismiss patients’ struggles and fail to offer effective treatments.
• Systemic Gaps: Lack of insurance reimbursement for medications and counseling, time constraints in busy clinics, and a lack of advocacy contribute to a system that fails these patients.
• Internalized Stigma: Patients themselves often internalize this bias, leading to shame, avoidance of medical care, and a reluctance to seek help.

Research from Harvard’s implicit bias studies has disturbingly shown that while biases against race, gender, and sexual orientation are decreasing, weight bias is the only one that has been increasing. This bias is not benign; it directly contributes to increased complications and mortality, independent of a patient’s BMI. When we fail to treat obesity, we are not just failing to help patients lose weight; we are failing to provide life-saving care. It starts with us, the providers. We must reframe our thinking and our language. We would never tell a patient with schizophrenia to “just stop listening to the voices.” It’s a chemical, neurological condition. The same is true for the powerful biological drivers of obesity.

Understanding Binge Eating Disorder: A Critical Diagnosis

As a clinician, I have seen that precise diagnosis opens doors to effective treatment. Binge Eating Disorder (BED) is a common and serious condition often co-occurring with obesity. It is characterized by:

• Eating an objectively large amount of food in a discrete period with a sense of loss of control.
• At least three of the following: eating more rapidly than normal, eating until uncomfortably full, eating when not hungry, eating alone due to embarrassment, and feeling disgusted, depressed, or guilty after the episode.
• Marked distress regarding binge eating.
• Frequency of at least weekly for a minimum of 3 months.
• Not regularly associated with compensatory behaviors such as purging, which differentiates it from bulimia nervosa.

These criteria align with the DSM-5-TR (American Psychiatric Association, 2022). The neurobiology of BED involves dysregulation of dopaminergic reward pathways and impaired inhibitory control circuits, making it a physiological issue rather than a willpower problem. By accurately aiming BED, I can align pharmacology, psychotherapy referrals, and structured nutrition to re-establish satiety rhythms and stabilize reward signaling.

A New Era of Obesity Pharmacotherapy: Tools for Change

For patients who have struggled with lifestyle changes alone, pharmacotherapy can be a powerful tool. However, our first principle must be: “First, do no harm.” A shocking clinical observation is that patients with obesity are more likely to be prescribed obesogenic medications—drugs that cause weight gain. Common culprits include certain antidepressants, antipsychotics, and some diabetes medications like sulfonylureas. In our practice, Dr. Cardenas and I always perform a thorough medication review, looking for weight-neutral or weight-loss-promoting alternatives whenever clinically appropriate.

Evidence-Based Pharmacologic Tools: What, Why, and How We Use Them

I individualize pharmacotherapy based on comorbidities, preferences, cost, and safety.

• Phentermine: This short-term sympathomimetic agent suppresses appetite through norepinephrine signaling. I use it sparingly as a bridge for jump-starting weight loss in carefully selected, low-cardiovascular-risk patients, as it requires close monitoring of blood pressure and heart rate.
• Orlistat (Xenical, Alli): This lipase inhibitor prevents about 30% of dietary fat from being absorbed. The mechanism also serves as a behavioral disincentive—eating a high-fat meal causes unpleasant GI side effects. We supplement with fat-soluble vitamins (A, D, E, K) as needed.
• Naltrexone/Bupropion (Contrave): This sophisticated combination targets the brain’s reward and appetite-control centers. Bupropion stimulates the POMC system to reduce appetite, while naltrexone blocks opioid receptors to override a negative feedback loop. It’s beneficial for patients with coexisting depression or reward-driven overeating but requires hypertension monitoring and slow titration.
• GLP-1 Receptor Agonists (Liraglutide, Semaglutide): These powerful agents mimic the natural gut hormone GLP-1 to increase fullness, slow stomach emptying, and regulate appetite signals in the brain. They are administered as injections.

• • Liraglutide (Saxenda): A daily injection, also known as Victoza for diabetes.
  • Semaglutide (Wegovy): A more potent, weekly injection that has shown significant weight loss results. It is also known as Ozempic, which is used for diabetes.

• Dual GIP/GLP-1 Receptor Agonist (Tirzepatide):

• • Tirzepatide (Zepbound): This groundbreaking weekly injectable targets two incretin pathways, demonstrating profound weight-loss results that rival those of some bariatric procedures. It is also known as Mounjaro for diabetes.

• Lisdexamfetamine (Vyvanse): While not approved for general obesity, this medication is FDA-approved for binge eating disorder (BED). It modulates catecholamine signaling to improve impulse control and reduce the frequency of bingeing. It can be an incredibly valuable tool for the right patient.

How We Decide and Monitor

Our choice of medication is highly personalized. For a patient with type 2 diabetes, a GLP-1 RA or tirzepatide is preferred for dual A1C and weight reduction. For a patient with depression, naltrexone-bupropion may be a good fit. For BED, lisdexamfetamine is a primary consideration. A key target is achieving at least a 5% body weight reduction by 12 weeks on a therapeutic dose. If this is not met, we reassess and consider switching agents.

The Role of Integrative Chiropractic Care in Weight Management

You might wonder how chiropractic care fits into this picture of hormones and pharmacology. The answer lies in a truly holistic, whole-body approach. At Injury Medical Clinic PA, my role as a chiropractor is foundational to our patients’ success. Excess weight places enormous biomechanical stress on the body.

• Spinal Misalignment and Nerve Function: Excess abdominal weight pulls the pelvis forward, creating a swayback posture (hyperlordosis). This strains back muscles and can cause vertebral misalignments (subluxations) that impinge on nerves. Chiropractic adjustments help restore proper alignment, reducing pain and improving nervous system function—the master control system for the entire body, including the endocrine system.
• Osteoarthritis and Joint Pain: The knees, hips, and lower back bear the brunt of excess weight. For every pound of body weight lost, there is a four-pound reduction in pressure on the knees. By managing joint pain and improving mobility through chiropractic care and rehabilitation, we enable patients to engage in physical activity. If it hurts to move, you won’t move. We break that cycle.
• Improving Overall Function and Well-being: When patients are no longer in constant pain, their sleep improves, their stress levels decrease (lowering cortisol), and their overall sense of well-being is enhanced. This creates a positive feedback loop, empowering them to adhere to their nutrition plan and stay active.

From my clinical observations, which I have shared on HealthCoach.Clinic and my professional page, a few patterns consistently emerge. Pain relief enables movement. Autonomic rebalancing through manual therapy and breathing exercises lowers stress eating. And a focus on movement quality before intensity prevents injury, allowing patients to build strength and preserve essential muscle mass, especially when using GLP-1 therapies.

Emerging Therapies Reshaping Obesity Care

The future of obesity treatment is incredibly promising. The pipeline is robust, with therapies that may offer even greater efficacy and targeted benefits.

• Retatrutide (Triple Agonist: GLP-1/GIP/Glucagon): Early studies show unprecedented weight loss (approximately 24% over 48 weeks), with evidence of improved lean mass preservation, potentially via glucagon-mediated energy expenditure.
• Oral GLP-1 Agonists: Oral semaglutide and other small-molecule agents, such as orforglipron, offer non-injectable options that could lower barriers to adherence.
• Combination Agents: Drugs like CagriSema (combining a GLP-1 with an amylin analog) are showing double-digit percentage weight loss in trials.
• Bimagrumab: A novel agent that works by blocking the activin receptor, this monthly infusion preferentially reduces fat mass while preserving or even increasing lean mass—an intriguing option for sarcopenic obesity.

These developments underscore a critical point: preserving lean mass during aggressive fat loss is paramount for sustaining metabolic rate and mobility. This is where the synergy of resistance training, adequate protein intake, and careful medication selection becomes vital.

---

Discovering the Benefits of Chiropractic Care- Video

---

Our Practical Roadmap: From Evaluation to Durable Results

Our step-by-step approach is designed to be comprehensive and patient-centered.

1. Comprehensive Evaluation: We conduct a full medical, functional, and psychological assessment to understand all contributing factors.
2. Remove Barriers: We de-prescribe obesogenic drugs and stabilize pain generators to enable activity.
3. Choose the Right Medication: We align pharmacotherapy with comorbidities, preferences, and safety profiles to set clear expectations.
4. Build the Foundation: We provide structured guidance on nutrition (protein-forward meals), exercise (progressive resistance training), and lifestyle (sleep and stress management).
5. Monitor and Iterate: We conduct frequent follow-ups to track vitals, labs, side effects, and progress, and titrate or pivot as needed.
6. Support Long-Term Maintenance: We transition the focus from weight loss to capability, helping patients build lifelong healthy habits.

Final Thoughts: A Personalized, Safe, and Integrated Future

If there is one guiding principle I want you to remember, it is this: first, do no harm. That means removing medications that worsen obesity, screening for contraindications, and individualizing therapy to the whole person. At Injury Medical Clinic PA, our collaborative model—with Dr. Cardenas providing rigorous medical oversight and my team optimizing movement, metabolism, and behavior—aims to deliver safe, sustainable outcomes rooted in modern, evidence-based methods. We believe this integrated approach is the future of effective weight management.

References

• American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.).
• Apovian, C. M., Aronne, L. J., Bessesen, D. H., et al. (2015). Pharmacological management of obesity: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 100(2), 342–362.
• Armstrong, M. J., Gaunt, P., Aithal, G. P., et al. (2016). Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN). The Lancet, 387(10019), 679–690.
• Davies, M. J., D’Alessio, D. A., Fradkin, J., et al. (2018). Management of hyperglycemia in type 2 diabetes, 2018. Diabetes Care, 41(12), 2669–2701.
• Garvey, W. T., Mechanick, J. I., Brett, E. M., et al. (2016). American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice, 22(Suppl 3), 1–203.
• Greenway, F. L., Dunayevich, E., Tollefson, G., et al. (2010). Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. The Journal of Clinical Investigation, 116(6), 1737-1751.
• Heymsfield, S. B., Coleman, L. A., Miller, R., et al. (2021). Effect of bimagrumab on body fat mass among adults with obesity. JAMA Network Open, 4(8), e2124542.
• Heymsfield, S. B., Wadden, T. A., Kahan, S., et al. (2017). Mechanisms, pathophysiology, and management of obesity. New England Journal of Medicine, 376, 254–266.
• Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., … & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216.
• Jastreboff, A. M., Kaplan, L. M., Frías, J. P., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine, 389, 514-526.
• Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., … & Yanovski, S. Z. (2014). 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation, 129(25_suppl_2), S102-S138.
• Kahn, B. B., & Flier, J. S. (2000). Obesity and insulin resistance. Journal of Clinical Investigation, 106(4), 473–481.
• Kessler, R. M., Hutson, P. H., Herman, B. K., & Potenza, M. N. (2016). The neurobiological basis of binge-eating disorder. Neuroscience & Biobehavioral Reviews, 63, 223–238.
• Lumeng, C. N., & Saltiel, A. R. (2011). Inflammatory links between obesity and metabolic disease. Journal of Clinical Investigation, 121(6), 2111–2117.
• McElroy, S. L., Hudson, J. I., Mitchell, J. E., et al. (2015). Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry, 72(3), 235–246.
• Münzberg, H., & Morrison, C. D. (2015). Structure, production and signaling of leptin. Molecular and Cellular Endocrinology, 418, 13- 23.
• Puhl, R. M., & Heuer, C. A. (2009). The stigma of obesity: a review and update. Obesity, 17(5), 941-964.
• Rubino, D. M., Greenway, F. L., Khalid, U., et al. (2022). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA, 327(2), 138-150.
• Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … & Wadden, T. A. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.

SEO Tags: Obesity Treatment, Weight Loss, Integrative Medicine, Chiropractic Care, Dr. Alex Jimenez, Functional Medicine, Pharmacotherapy, Semaglutide, Tirzepatide, Weight Bias, Appetite Regulation, El Paso TX, Injury Medical Clinic, Dr. Maria Cardenas, Binge Eating Disorder, Holistic Health, Musculoskeletal Health, naltrexone-bupropion, phentermine, orlistat, integrative chiropractic care, internal medicine collaboration, de-prescribing, metabolic health, rehabilitation, pain management, retatrutide, oral semaglutide